The estimated Net Worth of James J Bochnowski is at least $284 Thousand dollars as of 17 May 2023. Mr. Bochnowski owns over 1,280 units of Jaguar Health Inc stock worth over $2,557 and over the last 21 years he sold JAGX stock worth over $777. In addition, he makes $280,373 as Independent Chairman of the Board at Jaguar Health Inc.
James has made over 7 trades of the Jaguar Health Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 1,280 units of JAGX stock worth $1,446 on 17 May 2023.
The largest trade he's ever made was buying 180,582 units of Jaguar Health Inc stock on 23 July 2019 worth over $361,164. On average, James trades about 29,307 units every 126 days since 2003. As of 17 May 2023 he still owns at least 2,263 units of Jaguar Health Inc stock.
You can see the complete history of Mr. Bochnowski stock trades at the bottom of the page.
James J. Bochnowski serves as Independent Chairman of the Board of the Company. Mr. Bochnowski has served as the founder and Managing Member of Delphi Ventures, a venture capital firm. In 1980, Mr. Bochnowski co-founded Technology Venture Investors. Mr. Bochnowski holds an M.B.A. from Harvard University Graduate School of Business and a B.S. in Aeronautics and Astronautics from Massachusetts Institute of Technology.
As the Independent Chairman of the Board of Jaguar Health Inc, the total compensation of James Bochnowski at Jaguar Health Inc is $280,373. There are 6 executives at Jaguar Health Inc getting paid more, with Lisa Conte having the highest compensation of $1,433,160.
James Bochnowski is 76, he's been the Independent Chairman of the Board of Jaguar Health Inc since 2018. There are no older and 14 younger executives at Jaguar Health Inc.
James's mailing address filed with the SEC is C/O JAGUAR HEALTH, INC., 200 PINE STREET, SUITE 400, SAN FRANCISCO, CA, 94104.
Over the last 9 years, insiders at Jaguar Health Inc have traded over $596,652 worth of Jaguar Health Inc stock and bought 670,772 units worth $1,311,594 . The most active insiders traders include Capital Partners, L.P.Sagar..., James J Bochnowski, and Investments Ltd Burford Cap.... On average, Jaguar Health Inc executives and independent directors trade stock every 66 days with the average trade being worth of $27,901. The most recent stock trade was executed by Pravin R Chaturvedi on 17 May 2024, trading 871 units of JAGX stock currently worth $984.
jaguar health, inc. is a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. our wholly-owned subsidiary, napo pharmaceuticals, inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. our mytesi® (crofelemer) product is approved by the u.s. fda for the symptomatic relief of noninfectious diarrhea in adults with hiv/aids on antiretroviral therapy. canalevia™ is our lead animal prescription drug candidate, intended for treatment of various forms of diarrhea in dogs. equilevia™ is jaguar’s non-prescription product for total gut health in equine athletes. to read our full social media policy, please visit https://jaguar.health/social-media-policy/
Jaguar Health Inc executives and other stock owners filed with the SEC include: